Fig. 6

(A and B) WT embryos were treated with different doses of the MAP4K4 inhibitor PF06260933. (A) At 3 dpf, Map4k4 inhibition induced developmental defects including shortening of the body, small eyes (~), cloacal defects (closed square), pericardial edema (^), and thickening of the yolk extension (arrow) or reduced yolk constriction (dashed arrow). Representative lateral images are shown. (B) Representative ventral images of Alcian blue staining of the jaw cartilage at 5 dpf. At higher doses, the swollen hearts obscure the jaw. For clarity, the black dashed line outlines the head, the red dashed line outlines edematous heart, and the solid red line indicates the distance between the ceratohyal and Meckel’s cartilages. (C to E) Quantitation of abnormalities (C), body length (D), and jaw length (E) reveals increasing defects and shortening of both body and jaw in a dose-responsive manner. Scale bars, 500 (A) and 200 μm (B). Graphs: pale gray: vehicle (Veh); orange, drug treated. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by pairwise Student’s t test (D and E) compared to vehicle. ANOVA gives P < 0.0001 for (D) and (E). n numbers are inset to graphs in gray text. Error bars represent the SEM.